Perspectum and BluMaiden Biosciences Pte. Ltd. (“BluMaiden BioSciences”) Form Strategic Collaboration to Introduce Novel Insights into Clinical Trials

April 13, 2023

Perspectum Completes $19 Million Second Close of Series C Funding Led by Oppenheimer & Co. Inc. (“Oppenheimer”)

March 15, 2023

Perspectum Completes $36 Million First Close of Series C Funding Led by Oppenheimer Holdings

January 05, 2023

Leading Singaporean Diagnostic Center Increases MRI Capacity to Expand Patient Access to Perspectum’s LiverMultiScan

December 14, 2022

Perspectum and Nuance Collaborate to Scale Access to AI-Enabled Integrated Digital Care Platforms to Improve Patient Care for Metabolic Disease

November 28, 2022

FDA awards Perspectum major grant for the qualification of its noninvasive diagnostic biomarker to reduce liver biopsy in drug trials

September 27, 2022

LiverMultiScan shown to be a cost-effective alternative to liver biopsies for monitoring patients with autoimmune hepatitis

September 21, 2022

Perspectum Announces American Medical Association (AMA) Issues two Unique Category III CPT® Codes priced appropriately by the Centers for Medicare & Medicaid Services (CMS) for Noninvasive Biliary Anatomy Assessment With MRCP+

July 05, 2022

FDA Grants Clearance to Perspectum’s CoverScan – A New Platform-Based Tool to Assess Multiple Organs in One MRI Scan

May 22, 2022